Welcome to the Developmental Therapeutics Program
The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. Since its inception in 1955 by Congress, DTP has supported the development of more than 40 US-licensed anti-cancer agents through extensive collaborations with academic, pharmaceutical and biotechnology industries, including Paclitaxel, Romidepsin, Eribulin, Sipuleucel-T, and Dinutuximab (Ch14.18).
Today, most of DTP’s drug discovery and development services are available for academic and private researchers through applying for NCI Experimental Therapeutic program (NExT). Under this new framework, DTP continues to help academic and private sectors to overcome financial and technical barriers, particularly through supporting high-risk treatments for rare cancers, and facilitate the movement of promising therapeutic agents from scientists’ bench side to patients’ bed side.
DTP Branches and Offices
DTP services and resources:
DTP drug discovery and pre-clinic development services
Discovery services (NCI60 screening etc.) and pre-clinical support (pharmacology, toxicology and cGMP production etc.).
DTP repositories
Synthetic compounds, natural products, biological samples and standards.
DTP databases and searching/analysis tools
Bulk DTP chemical and biological data for searching and download, COMPARE analysis.
DTP grant programs
Grants for preclinical anti-cancer drug discovery and treatment, including small molecules, natural products and biological agents.
DCTD consultations
Advice on development of small molecules, biologics, and imaging products intended for cancer patients.
Stepping Stones
Access to discrete drug development studies for NCI/DCTD grantees.
About the Associate Director
Rosemarie Aurigemma, Ph.D., has been a programmatic leader in drug development for over 20 years. Her tenure as the Deputy Associate Director of DTP resulted in the launch of the Stepping Stones preclinical development program as well as the initiation and expansion of biopharmaceutical manufacturing support for adoptive cell therapies. She served as Acting Associate Director of the DCTD Developmental Therapeutics Program beginning in January 2021 until her permanent appointment in September 2021. As Associate Director, she will be managing the oversight and coordination of the programmatic, financial, and administrative functions for DTP's ten active branches.
More…